Chugai: Pipeline, Products, Performance, Potential

Table of Contents

Latest Results

EXECUTIVE SUMMARY

• Introduction
• Financial Performance 2005
  • Sales and Marketing Position
  • Income
    • Sales, Costs and Operating Income
  • Expenditure
    • Capital Expenditure
    • R&D Expenditure
  • Divisional Performance
  • Geographic Performance
    • Sales by Geographic Area
    • Sales by Geographic Area, 2005
• Company Strategy
  • Merger with Nippon Roche
  • Sunrise 2010
  • Mergers, Acquisitions and Divestitures
  • Key Agreements
  • Production
  • Employees
• Product/R&D Overview
  • Key Products
    • Recent Product Launches
    • Recent Product Approvals
  • R&D Strategy
    • Key R&D Projects
  • Sales Forecast
    • Sales of Major Products (2000A-2010E)
  • R&D Pipeline Overview
    • Discontinued R&D Projects
• Conclusions

PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT

• Major Products, Therapeutic Areas and Sales
• Breakdown of Sales by Therapeutic Area, 2005
• Top Selling Products, 2006
• R&D Pipeline - Japan
• R&D Pipeline - Overseas

• Haematological - Products
  • Major Launched Products
  • Epogin
    • Sales
    • Indications
    • Further Development
    • Patents
    • Competitor Products
    • Sales Forecast
  • Epogin Sales (2000A-2010E)
  • Neutrogin/Granocyte
    • Sales
    • Key Markets/Indications
    • Sales Forecast
  • Neutrogin Sales (2000A-2010E)
• Haematology - R&D
  • R&D Pipeline - Japan
  • R744
• Haematology - Summary
  • Growth Potential
  • Limiting Factors
• Anticancer, Chemotherapeutic - Products
  • Major Launched Products
  • Femara
  • Furtulon
  • Herceptin
    • Sales
    • Key Markets/Indications
    • Further Development
  • Rituxan
    • Sales
    • Indications
    • Safety Issues
    • Sales Forecast
  • Rituxan Sales (2000A-2010E)
  • Tamiflu
    • Sales
    • Indications
    • Competitor Products
    • Sales Forecast
  • Tamiflu Sales (2000A-2010E)
  • Xeloda
    • Sales
    • Indications
    • Further Development
• Anticancer, Chemotherapeutic - R&D
  • R&D Pipeline - Japan
  • Avastin
  • Omnitarg
  • Tarceva
• Anticancer, Chemotherapeutic - Summary
  • Growth Potential
  • Limiting Factors
• Cardiovascular, Respiratory - Products
  • Major Launched Products
  • Inhibace
  • Renagel
    • Sales
    • Markets/Indications
  • Rythmodan
    • Sales
    • Sales Forecast
  • Rythmodan Sales (2000A-2010E)
  • Sigmart/Ikorel
    • Sales
    • Licensees
    • Indications
    • Sales Forecast
  • Sigmart Sales (2000A-2010E)
• Cardiovascular, Respiratory - R&D
  • R&D Pipeline - Japan
  • Antevas (AVS)
• Cardiovascular, Respiratory - Summary
• Hormones, Vitamins, Tonic - Products
  • Major Launched Products
  • Alfarol
    • Sales
    • Sales Forecast
  • Alfarol Sales (2000A-2010E)
  • Oxarol/OCT
    • Sales
    • Further Development
• Hormones, Vitamins, Tonic - Summary
• Metabolic - R&D
  • Japanese R&D Pipeline
  • CHS13340
  • ED-71
  • Ibandronic Acid (R484)
  • R483
• Metabolic - Summary
• Gastrointestinal - Products
  • Major Launched Products
  • Kytril
    • Sales
  • Ulcerlmin
• Gastrointestinal - R&D
  • R&D Pipeline - Japan
  • R&D Pipeline - Overseas
  • Mitemcinal Fumarate (GM-611)
  • VAL
• Gastrointestinal - Summary
• Central Nervous System - Products
  • Amoban
• Central Nervous System - Summary
• Antibiotic - Products
  • Major Launched Products
  • Rocephin
    • Sales
    • Indications
• Other - Products
  • Major Launched Products
  • Actemra 200
    • Key Markets/Indications
    • Further Development
    • Clinical Trial Results
  • Pegasys
    • Sales
    • Indications
    • Further Development
• Other - R&D
  • R&D Pipeline - Japan
  • R&D Pipeline - Overseas

APPENDIX 1- FINANCIAL PERFORMANCE

• Full Year Results 2005
  • Sales, Costs and Operating Income
  • Profitability and Research Ratios
  • R&D Expenditure and Capital Expenditure
  • Current Assets, Liabilities and Ratio
  • Assets, Cash and Liquidity
  • Employees and Productivity

APPENDIX 3 - KEY AGREEMENTS

• Abgenix Inc
  • 3rd February 2003
• Cerus Corporation
  • 22nd December 2004
• Cambrex Bio Science Walkersville
  • 21st February 2006
• Eli Lilly
  • 13th December 1995
• Genzyme General
  • December 1994
• Roche
  • 5th April 2002
  • 3rd October 2002
  • 25th February 2003
  • 15th December 2003
  • 27th April 2004
• Xencor Inc
  • 10th January 2005

APPENDIX 4 - INFRASTRUCTURE

• Research and Development Facilities
• Manufacturing Facilities

APPENDIX 5 - KEY PHARMACEUTICAL

• SUBSIDIARIES/JOINT VENTURES
• Subsidiaries
• Joint Ventures

APPENDIX 6 - PRODUCT INDEX